The $2.5 Billion Bet on a Gene Therapy That Just Struck Out
Sarepta's Elevidys, the most closely watched gene therapy in rare disease, just failed its Phase III confirmatory trial, triggered a black box warning, and forced 500 layoffs. The fallout could reshape how the FDA handles gene therapy approvals for years to come.
Imagine spending a decade building the most ambitious gene therapy in rare disease history. You get the FDA to approve it, expand the label, and convince parents of boys with Duchenne muscular dystrophy that science finally has an answer. Then the confirmatory trial comes back, and the numbers just… aren't there.
That's where Sarepta Therapeutics finds itself right now. Its marquee gene therapy, Elevidys, failed a Phase III confirmatory study. The FDA is slapping on a black box warning for liver injury. And 500 employees, roughly 36% of the company, are cleaning out their desks.
This isn't just a bad quarter. It's an existential reckoning for the most closely watched gene therapy in the world.
What Elevidys Was Supposed to Be
Duchenne muscular dystrophy (DMD) is a brutal disease. It's caused by mutations in the gene that makes dystrophin, a protein muscles need to function. Without it, boys lose the ability to walk, usually by their early teens. Most don't survive past their 30s.
Elevidys was designed to be transformative: a one-time IV infusion that delivers a miniaturized version of the dystrophin gene directly into muscle cells using a viral vector (think of it as a molecular delivery truck). The idea is elegant. Give the body the genetic instructions it's missing, and let it start producing the protein on its own.
The FDA gave Elevidys accelerated approval in June 2023 for a narrow group of ambulatory boys aged 4 to 5. That approval was based on a surrogate endpoint, meaning the drug showed it could produce micro-dystrophin in muscle tissue. Whether that protein actually helped kids move better? That was supposed to be answered by the confirmatory trial.
The Trial That Couldn't Deliver
The confirmatory study, called EMBARK, enrolled 125 ambulatory boys aged 4 to 7 and randomized them to receive Elevidys or a placebo. The primary endpoint was straightforward: improvement in the North Star Ambulatory Assessment (NSAA), a 17-item motor function test, after one year.
Get tomorrow's biotech intelligence before your competitors.
Join thousands of biotech professionals who start their day with our free, daily briefing.
Both groups improved. The Elevidys arm gained 2.57 points on the NSAA scale. The placebo group gained 1.92 points. The gap between them? Just 0.65 points, with a p-value of 0.24. In clinical trial math, that's a miss. Not even close to the statistical significance threshold needed to declare victory.
To put it plainly: if you watched two kids, one treated and one not, you probably couldn't tell the difference after a year.
Here's the twist, though. Despite that miss, the FDA still granted traditional (full) approval for ambulatory patients in June 2024, expanding the label to all ambulatory individuals aged 4 and up. The agency's center director overruled internal reviewers, citing secondary endpoints and the totality of evidence. It was one of the most controversial regulatory decisions in recent memory. The European Medicines Agency, for its part, issued a flat-out negative opinion, saying the trial didn't show meaningful mobility improvement.
Then Came the Safety Crisis
If the efficacy story was complicated, the safety story turned dire. Multiple patient deaths among Elevidys-treated individuals (concentrated in non-ambulatory patients) triggered successive stock crashes of 20% to 40%. Sarepta paused shipments. The FDA asked for a halt. At one point, Sarepta reportedly pushed back on the FDA's request to stop distribution, a move analysts warned could damage management credibility.
Now the FDA has requested a black box warning on Elevidys for acute liver injury and liver failure, the most serious type of safety label the agency can impose. Sarepta has agreed to the change.
The non-ambulatory indication, which only ever had accelerated approval, is effectively frozen. Sarepta has paused dosing in that population while exploring additional immunosuppression protocols, including the drug sirolimus.
500 Jobs and a Strategic U-Turn
With its flagship product in regulatory limbo, Sarepta announced a sweeping restructuring. The company is cutting 500 positions and expects to save about $400 million annually starting in 2026. The workforce reduction alone should free up around $120 million in annual cash savings.
More telling than the layoffs is where Sarepta says it's heading next. The company is pivoting toward its siRNA platform and pausing work on several other programs. Translation: gene therapy is no longer the whole story. Sarepta is diversifying its bets, which is either prudent risk management or an admission that Elevidys can't carry the company alone. Probably both.
Wall Street's Verdict: Hope, but Hold the Champagne
Analyst sentiment has deteriorated sharply after the safety events.
Needham's Gil Blum slashed his Elevidys revenue forecast from $1.4 billion to $969 million and cut his price target from $125 to $50. William Blair's Sami Corwin called any FDA requirement for a new clinical trial in ambulatory patients "unprecedented" for a product with traditional approval.
The base case among analysts: Elevidys retains a restricted ambulatory indication with beefed-up safety monitoring, while non-ambulatory use stays frozen or gets pulled entirely. The bear case is scarier. New large-scale safety trials, further label cuts, and a commercial trajectory that can't sustain the company.
What This Means Beyond Sarepta
This saga isn't just about one company or one drug. It's a stress test for the entire gene therapy model.
The accelerated approval pathway was designed to get promising drugs to desperate patients faster, with the understanding that confirmatory data would follow. But when that data disappoints (and it has, repeatedly; 4 of 6 gene and RNA therapy accelerated approvals have later failed to demonstrate clinical benefit in controlled settings), the system faces an impossible question: do you pull a treatment from kids who have no alternatives?
FDA leadership has changed since the original Elevidys approval. The new regime appears less willing to overrule staff reviewers on close calls. For the next wave of gene therapy developers, including REGENXBIO (now targeting a 2027 filing) and Genethon (now in Phase 3 in the UK and France), the regulatory bar just got higher.
Meanwhile, DMD families are caught in the middle. Corticosteroids remain the backbone of care. Exon-skipping drugs cover only about 30% of patients. And the gene therapy that was supposed to change everything is now fighting for its survival on the market.
Sarepta isn't dead. Three-year EMBARK follow-up data reported in January 2026 showed roughly a 70% reduction in the rate of decline on timed functional endpoints (Time to Rise and 10-meter walk/run) compared to an external control group, which analysts called encouraging for the long-term efficacy story. But as one observer noted, better long-term data doesn't resolve near-term safety fears or the prospect of FDA-mandated new trials.
The biggest gene therapy bet in rare disease just got a lot more complicated. And the answer to whether it was worth it may take another decade to know.
Deals & M&A4 min read
Novo Nordisk Just Paid $327M for a Molecular GPS System
Novo Nordisk licensed a French biotech's molecular delivery platform in a deal worth up to $327 million, betting that getting drugs past the blood-brain barrier is the next great competitive advantage. The deal is part of a massive pharma arms race over targeted tissue delivery that's reshaping biotech dealmaking.
